Literature DB >> 28077719

Suppressing N-Acetyl-l-Aspartate Synthesis Prevents Loss of Neurons in a Murine Model of Canavan Leukodystrophy.

Jiho Sohn1, Peter Bannerman1, Fuzheng Guo1, Travis Burns1, Laird Miers1, Christopher Croteau1, Naveen K Singhal2, Jennifer A McDonough2, David Pleasure3.   

Abstract

Canavan disease is a leukodystrophy caused by aspartoacylase (ASPA) deficiency. The lack of functional ASPA, an enzyme enriched in oligodendroglia that cleaves N-acetyl-l-aspartate (NAA) to acetate and l-aspartic acid, elevates brain NAA and causes "spongiform" vacuolation of superficial brain white matter and neighboring gray matter. In children with Canavan disease, neuroimaging shows early-onset dysmyelination and progressive brain atrophy. Neuron loss has been documented at autopsy in some cases. Prior studies have shown that mice homozygous for the Aspa nonsense mutation Nur7 also develop brain vacuolation. We now report that numbers of cerebral cortical and cerebellar neurons are decreased and that cerebral cortex progressively thins in AspaNur7/Nur7 mice. This neuronal pathology is prevented by constitutive disruption of Nat8l, which encodes the neuronal NAA-synthetic enzyme N-acetyltransferase-8-like. SIGNIFICANCE STATEMENT: This is the first demonstration of cortical and cerebellar neuron depletion and progressive cerebral cortical thinning in an animal model of Canavan disease. Genetic suppression of N-acetyl-l-aspartate (NAA) synthesis, previously shown to block brain vacuolation in aspartoacylase-deficient mice, also prevents neuron loss and cerebral cortical atrophy in these mice. These results suggest that lowering the concentration of NAA in the brains of children with Canavan disease would prevent or slow progression of neurological deficits.
Copyright © 2017 the authors 0270-6474/17/370413-09$15.00/0.

Entities:  

Keywords:  Canavan disease; N-acetyl-l-aspartate; N-acetyltransferase-8-like; aspartoacylase; myelin; neuron

Mesh:

Substances:

Year:  2017        PMID: 28077719      PMCID: PMC5242397          DOI: 10.1523/JNEUROSCI.2013-16.2016

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  63 in total

Review 1.  White matter lactate--does it matter?

Authors:  J E Rinholm; L H Bergersen
Journal:  Neuroscience       Date:  2013-10-12       Impact factor: 3.590

2.  Natural history of Canavan disease revealed by proton magnetic resonance spectroscopy (1H-MRS) and diffusion-weighted MRI.

Authors:  C G Janson; S W J McPhee; J Francis; D Shera; M Assadi; A Freese; P Hurh; J Haselgrove; D J Wang; L Bilaniuk; P Leone
Journal:  Neuropediatrics       Date:  2006-08       Impact factor: 1.947

3.  Endogenous aspartoacylase expression is responsive to glutamatergic activity in vitro and in vivo.

Authors:  Jeremy S Francis; Louise Strande; Amy Pu; Paola Leone
Journal:  Glia       Date:  2011-05-23       Impact factor: 7.452

4.  Axonal dystrophy in a case of Canavan's spongy degeneration.

Authors:  S Kamoshita; G B Reed; M J Aguilar
Journal:  Neurology       Date:  1967-09       Impact factor: 9.910

5.  Neuronal nuclear antigen (NeuN): a marker of neuronal maturation in early human fetal nervous system.

Authors:  H B Sarnat; D Nochlin; D E Born
Journal:  Brain Dev       Date:  1998-03       Impact factor: 1.961

6.  Nur7 is a nonsense mutation in the mouse aspartoacylase gene that causes spongy degeneration of the CNS.

Authors:  Maria Traka; Robert L Wollmann; Sonia R Cerda; Jason Dugas; Ben A Barres; Brian Popko
Journal:  J Neurosci       Date:  2008-11-05       Impact factor: 6.167

7.  Combining Double Fluorescence In Situ Hybridization with Immunolabelling for Detection of the Expression of Three Genes in Mouse Brain Sections.

Authors:  Sarah Jolly; Alexander Fudge; Nigel Pringle; William D Richardson; Huiliang Li
Journal:  J Vis Exp       Date:  2016-03-26       Impact factor: 1.355

8.  Oligodendrocytes promote neuronal survival and axonal length by distinct intracellular mechanisms: a novel role for oligodendrocyte-derived glial cell line-derived neurotrophic factor.

Authors:  Alastair Wilkins; Henry Majed; Robert Layfield; Alastair Compston; Siddharthan Chandran
Journal:  J Neurosci       Date:  2003-06-15       Impact factor: 6.167

9.  L-Lactate-Mediated Neuroprotection against Glutamate-Induced Excitotoxicity Requires ARALAR/AGC1.

Authors:  Irene Llorente-Folch; Carlos B Rueda; Irene Pérez-Liébana; Jorgina Satrústegui; Beatriz Pardo
Journal:  J Neurosci       Date:  2016-04-20       Impact factor: 6.167

10.  Correlations of behavioral deficits with brain pathology assessed through longitudinal MRI and histopathology in the R6/2 mouse model of HD.

Authors:  Ivan Rattray; Edward Smith; Richard Gale; Kaoru Matsumoto; Gillian P Bates; Michel Modo
Journal:  PLoS One       Date:  2013-04-04       Impact factor: 3.240

View more
  8 in total

1.  Pathophysiology and Treatment of Canavan Disease.

Authors:  David Pleasure; Fuzheng Guo; Olga Chechneva; Peter Bannerman; Jennifer McDonough; Travis Burns; Yan Wang; Vanessa Hull
Journal:  Neurochem Res       Date:  2018-12-08       Impact factor: 3.996

Review 2.  Metabolic and Cellular Compartments of Acetyl-CoA in the Healthy and Diseased Brain.

Authors:  Agnieszka Jankowska-Kulawy; Joanna Klimaszewska-Łata; Sylwia Gul-Hinc; Anna Ronowska; Andrzej Szutowicz
Journal:  Int J Mol Sci       Date:  2022-09-03       Impact factor: 6.208

3.  Therapeutic development for Canavan disease using patient iPSCs introduced with the wild-type ASPA gene.

Authors:  Jianfei Chao; Lizhao Feng; Peng Ye; Xianwei Chen; Qi Cui; Guihua Sun; Tao Zhou; E Tian; Wendong Li; Weidong Hu; Arthur D Riggs; Reuben Matalon; Yanhong Shi
Journal:  iScience       Date:  2022-05-11

4.  Brain Nat8l Knockdown Suppresses Spongiform Leukodystrophy in an Aspartoacylase-Deficient Canavan Disease Mouse Model.

Authors:  Peter Bannerman; Fuzheng Guo; Olga Chechneva; Travis Burns; Xiaoqing Zhu; Yan Wang; Bokyung Kim; Naveen K Singhal; Jennifer A McDonough; David Pleasure
Journal:  Mol Ther       Date:  2018-01-10       Impact factor: 11.454

5.  Sox2 Is Essential for Oligodendroglial Proliferation and Differentiation during Postnatal Brain Myelination and CNS Remyelination.

Authors:  Sheng Zhang; Xiaoqing Zhu; Xuehong Gui; Christopher Croteau; Lanying Song; Jie Xu; Aijun Wang; Peter Bannerman; Fuzheng Guo
Journal:  J Neurosci       Date:  2018-01-15       Impact factor: 6.167

6.  Increasing N-acetylaspartate in the Brain during Postnatal Myelination Does Not Cause the CNS Pathologies of Canavan Disease.

Authors:  Abhilash P Appu; John R Moffett; Peethambaran Arun; Sean Moran; Vikram Nambiar; Jishnu K S Krishnan; Narayanan Puthillathu; Aryan M A Namboodiri
Journal:  Front Mol Neurosci       Date:  2017-06-02       Impact factor: 5.639

Review 7.  AGC1 Deficiency: Pathology and Molecular and Cellular Mechanisms of the Disease.

Authors:  Beatriz Pardo; Eduardo Herrada-Soler; Jorgina Satrústegui; Laura Contreras; Araceli Del Arco
Journal:  Int J Mol Sci       Date:  2022-01-04       Impact factor: 5.923

8.  Uncoupling N-acetylaspartate from brain pathology: implications for Canavan disease gene therapy.

Authors:  Georg von Jonquieres; Ziggy H T Spencer; Benjamin D Rowlands; Claudia B Klugmann; Andre Bongers; Anne E Harasta; Kristina E Parley; Jennie Cederholm; Orla Teahan; Russell Pickford; Fabien Delerue; Lars M Ittner; Dominik Fröhlich; Catriona A McLean; Anthony S Don; Miriam Schneider; Gary D Housley; Caroline D Rae; Matthias Klugmann
Journal:  Acta Neuropathol       Date:  2017-11-07       Impact factor: 17.088

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.